The endeavor will use Biolidic’s ClearCell FX1 System and Sysmex’s molecular imaging flow cytometer MI-FCM in Japan and Singapore, respectively.
SINGAPORE (Feb 20): Biolidics Limited has established a strategic partnership with Sysmex Corporation, a Tokyo Stock Exchange-listed supplier of hematology instruments, to collaborate on the development of laboratory assays in the field of circulating tumour cells.
